RxDoctor Payments Data

Alexandra Wilson, PA

Physician Assistant · Beavercreek, OHNPI 1346821212

Payments from drug & device makers

$1,833in general payments, 2019–2025

Across 26 payments — averaging $70.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BETA Bionics, Inc.$378
  • Boehringer Ingelheim$257
  • Novo Nordisk$244
  • Dexcom, Inc.$236
  • Insulet Corporation$220
  • AbbVie$118
  • plus $380 from 9 others

What the payments were for

  • Food & beverage$1,833100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,833 in reported general payments places this provider in the 85th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$14,146
Medicare patients
84
Services billed
268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide233$284,436
OzempicSemaglutide197$231,375
TrulicityDulaglutide151$194,590
JardianceEmpagliflozin89$101,396
FarxigaDapagliflozin Propanediol80$97,052
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog62$89,146
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/765$67,083
Soliqua 100-33Insulin Glargine/Lixisenatide55$62,090
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog70$54,426
Fiasp FlextouchInsulin Aspart (Niacinamide)26$34,408
FiaspInsulin Aspart (Niacinamide)11$23,519
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$23,316
Humalog Kwikpen U-100Insulin Lispro73$22,870
Lantus SolostarInsulin Glargine,hum.Rec.Anlog96$16,987
TradjentaLinagliptin19$15,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$244$259,319220 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$257$127,911119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Beavercreek

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →